supernus biogen - Search News

News

Supernus To Acquire Sage

Zacks Investment Research on … · 16h

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal

Sage Therapeutics SAGE announced that Supernus Pharmaceuticals SUPN has agreed to acquire SAGE through a tender offer of $8.50 per share in cash, totaling around $561 million. Additionally, shareholders will receive a non-tradable contingent value right (CVR) worth up to $3.

Reuters on MSN · 1d

Supernus enters depression drug market with up to $795 million Sage deal

Supernus Pharmaceuticals will acquire Sage Therapeutics in a deal worth up to $795 million, gaining access to the only postpartum depression pill approved in the United States, the companies said on Monday.

Seeking Alpha · 1d

Supernus To Acquire Sage: A Smart Move, Despite Both Pharmas' MDD Woes

Supernus Pharmaceuticals (SUPN) acquires Sage Therapeutics (SAGE), enhancing its CNS portfolio with Zurzuvae's potential. Read my analysis on this acquisition.

After rebuffing Biogen, Sage pairs off with Supernus

The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...

GlobalData on MSN1d

Supernus makes depression drug play with $795m Sage buyout

After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill ...

Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus

Stifel analysts said the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in ...

1d

Sage, following Setbacks, to sell to Supernus for $561M

In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results